Divi's Laboratories Limited
Momentum (89/100) does the heavy lifting; valuation (4/100) is the drag.
ExpensiveOvervaluedOur blended model reads Divi's Laboratories Limited as a Hold at 45/100. At ₹7,784.5 it trades above our blended DCF and relative-multiples fair value of ₹3,892.25, about 50% downside to that estimate — we read it as overvalued by 50%. On 70.0x trailing earnings it sits pricier than the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹7,784.5. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹7,059.47 implies about 9% downside across 30 analysts. It clears 8 of 13 investability checks, with durability 86, valuation 7 and momentum 89 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹3,113.8.
Analyst views
1-year price
EOD · 2026-07-2952-week range
+0.00% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 16.2%
- Pass: Low debt (D/E < 0.5): 0.00x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 10%
- Pass: Earnings growing: 14%
- Pass: Net margin ≥ 10%: 24.3%
- Pass: Current ratio > 1.5: 5.43
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 34.88
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter52.0%
- Institutions29.7%
- Public & other18.3%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (24.3%).
- Trading near its 52-week high.
- Financially solid — Altman Z 34.88.
Bear case
Weaknesses
- Weak Piotroski score (3/9).
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Divi's Laboratories Limited
Divi's Laboratories manufactures and sells generic active pharmaceutical ingredients, intermediates, and nutraceuticals across India, North America, Asia, Europe, and internationally. The company provides custom synthesis contract manufacturing services for APIs and intermediates, and supplies carotenoids including beta carotene, astaxanthin, lycopene, and canthaxanthin, along with lutein and vitamins for food, beverage, and dietary applications.
Divi's Laboratories Limited — frequently asked questions
Is Divi's Laboratories Limited a buy, hold or sell?
StocksWizard currently rates Divi's Laboratories Limited (DIVISLAB) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Divi's Laboratories Limited's fair value?
Our blended DCF and relative-valuation model estimates Divi's Laboratories Limited's fair value at about ₹3,892.25, versus a current price of ₹7,784.5 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Divi's Laboratories Limited financially healthy?
Divi's Laboratories Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Divi's Laboratories Limited's share price performed?
Divi's Laboratories Limited is up 20% over three months, and last traded at ₹7,784.5. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.